Translating the MDS flow cytometric score into clinical practice.
Cytometry B Clin Cytom
; 88(3): 207-9, 2015.
Article
en En
| MEDLINE
| ID: mdl-25490972
ABSTRACT
Myelodysplastic syndromes (MDS) are classified by the WHO as myeloid neoplasms, and are characterized by cytopenia and dysplasia in one or more myeloid cell lines. Recently, a flow cytometric score (FCM-score) was published capable of discriminating low-grade MDS from non-clonal cytopenias (Della Porta et al., 2012). We tested the applicability of the FCM-score in a patient population from a large peripheral teaching hospital in The Netherlands. The evaluation of the proposed FCM score in low-grade MDS showed a high sensitivity and specificity, and clinically significant positive and negative likelihood ratios. The use of CD10 and CD19 positivity to identify progenitor B-cell blasts provided a specific and precize method to separate progenitor B-cell blasts from myeloid blasts within the CD34+/low CD45+ population and may be more convenient compared to the published method using low SSC and CD45 expression. This study confirms the value of utilizing the FCM-score in our patient population.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Síndromes Mielodisplásicos
/
Células de la Médula Ósea
/
Antígenos CD
/
Células Precursoras de Linfocitos B
/
Citometría de Flujo
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
País/Región como asunto:
Europa
Idioma:
En
Revista:
Cytometry B Clin Cytom
Año:
2015
Tipo del documento:
Article
País de afiliación:
Países Bajos